Phase 3 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a slow-growing, spread-out type of brain tumour (low-grade glioma) and have had surgery to remove all or part of the tumour, or at least a biopsy to confirm the diagnosis.
- People whose doctors recommend brain radiation therapy because of higher-risk features, such as the tumour not being fully removed or being over 40 years old at the time of surgery.
- People who are in reasonably good general health, as measured by standard medical scoring tools (confirm with trial site for exact score requirements).
Who may not be able to join:
- People whose tumour has been confirmed by laboratory testing to be the most aggressive type of brain tumour (grade IV glioma, also known as glioblastoma multiforme) or the least aggressive grade I type (such as pilocytic astrocytoma).
- People whose brain scans show a widespread pattern of tumour growth throughout the brain, known as gliomatosis cerebri.
- People who have previously received any form of radiation therapy to the brain for any reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +886-33281200
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary endpoint is delayed recall, as determined by the change/decline in verbal memory (WMS III- Word List score) from the baseline assessment to 4 months after the start of postoperative adjuvant RT.; The primary endpoint is delayed recall, as determined by the change/decline in non-verbal memory (WMS III- Visual Reproduction score) from the baseline assessment to 4 months after the start of postoperative adjuvant RT.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.